---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-003192"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T03:39:17.376037+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Xenetic Biosciences reports Q1 2024 net loss of $1.2M; cash at $7.8M

## Summary
- Net loss of approximately $1.2M for Q1 2024; R&D expenses up 58.6% to $0.9M on DNase preclinical work.
- Ended quarter with $7.8M cash; advancing DNase oncology program towards Phase 1 for solid tumors.
- Expects multiple preclinical data readouts in H2 2024 to guide clinical development strategy.
- G&A expenses decreased 9.8% to $0.8M compared to prior year quarter.

## SEC filing metadata
- accession: 0001683168-24-003192
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316824003192/0001683168-24-003192-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316824003192/xenetic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-003192
- JSON: https://secwatch.observer/filing/0001683168-24-003192.json
- Plain text: https://secwatch.observer/filing/0001683168-24-003192.txt

## Key facts
- Earnings Releases
  Xenetic Biosciences, Inc. reported first quarter of 2024 results: net income Net loss for the quarter ended March 31, 2024 was approximately $1.2 million..
  - Period: first quarter of 2024
  - Net income: Net loss for the quarter ended March 31, 2024 was approximately $1.2 million.
  - Result: reported results
  source text: On May 10, 2024, Xenetic Biosciences, Inc. (the “Company”) issued a press release announcing results for the three months ended March 31, 2024 and providing a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534525/000168316824003192/0001683168-24-003192-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.